The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development

• Published in: American journal of respiratory and critical care medicine Vol. 193; no. 6; pp. 662 - 672
• Main Authors: Allinson, James P, Hardy, Rebecca, Donaldson, Gavin C, Shaheen, Seif O, Kuh, Diana, Wedzicha, Jadwiga A
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 15.03.2016
• Subjects: Adult; Age Factors; Aging - physiology; Chronic Disease; Disease Progression; Female; Humans; Lung - physiopathology; Male; Middle Aged; Mucus - physiology; Odds Ratio; Original; Pulmonary Disease, Chronic Obstructive - physiopathology; Risk Factors; Smoking - physiopathology; Young Adult; chronic bronchitis; chronic mucus hypersecretion; cough; smoking; COPD
• ISSN: 1073-449X; 1535-4970
• DOI: 10.1164/rccm.201511-2210oc

Chronic mucus hypersecretion (CMH) is common among smokers and is associated with chronic obstructive pulmonary disease development and progression. To understand how the relationships between smoking, CMH, and chronic obstructive pulmonary disease develop during adult life, and facilitate earlier disease detection and intervention. We analyzed data on CMH, smoking, and lung function prospectively collected by the Medical Research Council National Survey of Health and Development, a nationally representative British cohort followed since birth in 1946. We analyzed the longitudinal relationships between smoking and CMH, how symptoms during life related to airflow limitation at 60-64 years, and how CMH duration between ages 43 and 60-64 years related to concurrent FEV1 decline. From 5,362 individuals enrolled at birth, 4,427 contributed data between ages 20 and 64 years (52% male; 63% ever-smoker). Among smokers CMH prevalence escalated between ages 36 and 43 from 7.6 ± 2.0% to 13.0 ± 2.6%. At these ages, symptoms were associated with a higher risk of subsequent airflow limitation (odds ratio [95% confidence interval], 3.70 [1.62-8.45] and 4.11 [1.85-9.13], respectively). Across adult life, CMH followed a dynamic remitting-relapsing course. Symptom prevalence following smoking cessation returned to levels seen among never-smokers. The longer CMH was present across three occasions (ages 43, 53, and 60-64 yr), the greater the concurrent FEV1 decline, corresponding to an additional decrement of 3.6 ± 2.5 ml/yr per occasion that CMH was present (P = 0.005). CMH among middle-aged smokers represents an early developmental phase of chronic obstructive pulmonary disease. Smoking-related CMH usually resolves following smoking cessation but the longer its duration the greater the FEV1 lost, suggesting the course of CMH across adult life may reflect the underlying course of airway disease activity.